Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | 112.04% | 173.90% | 39,283.33% | 922.97% | -173.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 112.04% | 173.90% | 39,283.33% | 922.97% | -173.39% |
| Cost of Revenue | 724.38% | 1,555.23% | 356.17% | 404.84% | -133.54% |
| Gross Profit | -165.67% | -305.90% | -243.29% | -234.10% | -259.11% |
| SG&A Expenses | -51.35% | -32.31% | -7.70% | 7.26% | 14.35% |
| Depreciation & Amortization | -15.74% | -17.82% | -18.95% | 17.76% | 56.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.90% | 4.34% | 19.00% | 39.86% | 1.39% |
| Operating Income | 24.49% | 4.22% | -10.98% | -30.13% | -53.69% |
| Income Before Tax | 29.53% | 31.62% | 14.61% | 15.68% | -63.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.53% | 31.62% | 14.61% | 15.68% | -63.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.53% | 31.62% | 14.61% | 15.68% | -63.35% |
| EBIT | 24.49% | 4.22% | -10.98% | -30.13% | -53.69% |
| EBITDA | 24.05% | -0.42% | -18.85% | -33.18% | -50.11% |
| EPS Basic | 33.80% | 36.01% | 20.30% | 22.51% | -50.60% |
| Normalized Basic EPS | 46.06% | 42.63% | 27.17% | 28.76% | -44.20% |
| EPS Diluted | 33.80% | 36.01% | 20.30% | 22.51% | -50.60% |
| Normalized Diluted EPS | 46.06% | 42.63% | 27.17% | 28.76% | -44.20% |
| Average Basic Shares Outstanding | 5.23% | 6.03% | 7.18% | 9.26% | 9.24% |
| Average Diluted Shares Outstanding | 5.23% | 6.03% | 7.18% | 9.26% | 9.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |